ABOUT VAD THERAPY Advanced Heart Failure

HEART FAILURE, A SERIOUS AND GROWING PROBLEM

heart failure affects an estimated 6.5 million people in the United States.

Heart failure affects an estimated 6.5 million people in the United States.

heart failure affects an estimated 26 million people worldwide

Heart failure affects an estimated 26 million people worldwide.

VAD Therapy can be an essential part of your Heart Failure Program

Ventricular assist devices (VADs) are transforming the treatment of advanced heart failure patients by providing another possible solution to a growing problem.

VAD THERAPY IS UNDERUTILIZED IN ADVANCED HEART FAILURE PATIENTS

less than five percent of patients eligible for VAD therapy receive the technology
  • Of incident hospitalized heart failure (HF) events, 53% had HF with a reduced ejection fraction.2
  • More than 240,000* patients with systolic HF who are under the age of 75 could potentially benefit from VAD therapy.

*Calculations based on references 2,3,4, and 5.

INDICATORS OF WORSENING HEART FAILURE

T

An indicator of worsening or advanced heart failure is two hospital readmissions within the past year.

I

An indicator of worsening or advanced heart failure is if Inotropes have been considered for the patient.

M

An indicator of worsening or advanced heart failure is if medical therapy has been optimized.

E

An indicator of worsening or advanced heart failure is an ejection fraction of less than 35 percent.

VAD THERAPY MAY LEAD TO A LIFE SAVED

VAD therapy is part of the field of Mechanical Circulatory Support (MCS). VADs are mechanical devices designed to help a weakened heart pump blood throughout the body by moving blood from the left ventricle and pumping it into the ascending aorta. VADs positively impact cardiac output and help alleviate the symptoms of heart failure.

The HeartWare™ HVAD™ Pump is the smallest, full support centrifugal VAD designed to be implanted completely within the pericardial space.9

Patient Survival and QOL are Improved

The overall survival of patients receiving continuous flow LVADs is 89% at 12 months and 87% at 24 months.5

When managing a patient with advanced heart failure, consider discussing referral for VAD therapy with the HeartWare HVAD System, while the patient still has time to make the choice.


1

AHA Heart Disease and Stroke Statistics. Circulation. 2017.

2

Benjamin EJ, et al. Circulation. 2017;135:e146-e603. Corrections in: Circulation. 2017;135:e646, Circulation. 2017;136:e196.

3

Heidenreich PA, et al. Circ Heart Fail. 2013;6:606-619.

4

Kirklin JK, et al. J Heart Lung Transplant. 2017;36:1080-1086.

5

Presented at ISHLT 2018, Nice, France

6

Yancy C, et al. J Am Coll Cardiol. 2018;71:201-230.

7

Ginwalla M, Tofovic DS. Current Status of Inotropes in Heart Failure. Heart Fail Clin. October 2018;14(4):601-616.

8

Peura JL, et al. Circulation. 2012;126:2648-2667.

9

HVAD System Instructions for Use. HeartWare Inc., Framingham, MA, USA. (01/2017).
HeartMate 3 Left Ventricular Assist System, Instructions for Use. Thoratec
Corporation, Pleasanton, CA, USA (2/2015).